NCT00693121View on ClinicalTrials.gov

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2019

Conditions
Traumatic Brain InjuryPosttraumatic Confusional StateDelirium
Interventions
DRUG

Amantadine hydrochloride

100mg administered orally twice daily x 14 days

DRUG

Placebo capsule

capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days

Trial Locations (1)

39216

Methodist Rehabilitation Center, Jackson

All Listed Sponsors
collaborator

U.S. Department of Education

FED

lead

Methodist Rehabilitation Center

OTHER

NCT00693121 - Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State | Biotech Hunter | Biotech Hunter